Systemic fungal infections in immunocompromised patients;Sistemske gljivične infekcije u imunokompromitiranih bolesnika

Acta Medica Croatica

Volumn 58, Issue 4, 2004, Pages 251-261

  Županić Krmek, Dubravka ^a   Nemet, Damir ^b  

^a University Hospital Sveti Duh   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Immunocompromised persons; Opportunistic fungal infections

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC ACCURACY; FUSARIUM; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; LEUKEMIA; MORBIDITY; MORTALITY; MUCOR; MYCOSIS; NEUTROPENIA; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARD; TECHNIQUE; TRICHOSPORON; OPPORTUNISTIC INFECTION;

HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; OPPORTUNISTIC INFECTIONS; RISK FACTORS;

EID: 12344284707     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Pfaller M. Epidemiology and control of fungal infections. Clin Infect Dis 1994; 19 (suppl 1): S8-13
2. Becq-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990. J Infect Dis 1993; 167: 1247-51.
3. Bodey G, Bueltman B, Duguid W. i sur. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
4. Pizzo PA, Meyers J, Freifeld AG, Walsh T. Infections in cancer patient. U: De Vita VT, Hellman S, Rosenberg SA. Cancer: Principles et practice of oncology. Philadelphia: JB Lippincott, 1993; 2292-333.
5. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17 Suppl. 6: 10-3.
6. Hadley S, Kachmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9: 1045-74.
7. Kappe R, Levitz S, Harrison TS i sur. Recent advances in cryptococcosis, candidiasis and coccidioidomycosis complicating HIV infection. Med Mycol 1998; 36 Suppl. 1: 207-15.
8. Wheat Lj, Connolly-Stringfield PA, Baker RL i sur. Disseminated histoplasmosis in the aquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine 1990; 69: 361-74.
9. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23: 125-30.
10. Marcon MJ, Powell DA. Epidemiology, diagnosis, and management of Malassezia furfur systemic infection. Diagn Microbiol Infect Dis 1987; 7: 161-75.
11. Bodey GP, Buckley H, Sathe Ys, Freireich EJ. Quantitative relationships between circulating lekocytes and infections in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
12. Poplack DG, Laese MR. The mononuclear phagocytic system. U: Stiehm E, Fulginetti V. Immunologic disorders of infants and children. Philadelphia: WB Saunders Co, 1980; 109.
13. Fisher RI, DeVita VT, Bostick F. Persistent immunologic abnormalites in long term survivors of advanced Hodgkins Disease. Ann Intern Med 1980; 92: 595-99.
14. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Am J Med 1981; 71. 363. 70.
15. Fitzpatrick JJ, Topley HE. Ampicillin therapy and Candida outgrowth. Am J Med Sci 1966; 252: 310-3.
16. Opal SM, Asp AA, Cannady PB i sur. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergilosis with hospital construction. J Infect Dis 1986; 153: 634-37.
17. Stone HH, Kolb LD, Currie CA, Geheber GE, Cuzzel JZ. Candida sepsis. Pathogenesis and principles of treatment. Ann Surg 1974; 179: 697-710.
18. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7: 646-55.
19. Dupont B, Denning DW, Mamot D, Sugar A, Viviani MA, Sirisanthana T. Mycoses in AIDS patients. J Med Vet Mycol 1994; 32 (Suppl. 1): 65-67.
20. Groll A, Walsh T. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7 (suppl 2): 8-24
21. Bodey G. Candididiasis: a growing concern. Am J Med 1984; 77: 1-48.
22. Bodey GP, Annaissie EJ. Chronic systemic candidiasis. Eur J Clin Microbiol Infect Dis 1989; 8: 855-7.
23. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis 1994; 7: 456-62.
24. Bennett JE: Rapid diagnosis of candidiasis and aspergillosis. Rev Infect Dis 1987; 9: 398-402.
25. Schimpff S. Surveillance cultures. J Infect Dis 1981; 144: 81-4.
26. Goldberg PK, Kozinn PJ, Wise J, Nouri N, Brooks RB. Incidence and significance of candiduria. JAMA 1979; 241: 582-4.
27. Kelly MT, Roberts FJ, Henry D, Geere I, Smith JA. Clinical comparison of Isolator and BACTEC 660 resin media for blood culture. J Clin Microbiol 1990; 28: 1925-27.
28. Yu VL, Muder RR, Poorsatar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis: results from a three-years prospective study. Am J Med 1986; 81: 249-54.
29. Weiner MH. Antigenemia detected by RIA in systemic aspergillosis. Ann Intern Med 1980; 92: 773-96.
30. Obayashi T, Yoshida M, Mori T i sur. Plasma (1-3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
31. Spredbury C, Holden D, Aufauvre-Brown A, Bainbridge B. Detection of Aspergillus fumigatus by polymerase chain reaction. J Clin Microbiol 1993; 31: 615-21.
32. Morace G, Pagano L, Sanguinetti M i sur. PCR-restriction enzyme analysis for dectection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol 1999; 37: 1871-5.
33. Maertens J, Verhaegen J, Demuuynk H i sur. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8.
34. Horvath J, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171-8.
35. Pittet D, Monod M, Suter PM, Frenk G, Auckenthaler R. Candida colonisation and subsequent infections in critically ill surgical patients. Ann Surg 1994; 6: 751-8.
36. Pizzo PA, Schimpff SC. Strategies for prevention of infection in the myelosupressed or immunosuppresed cancer patient. Cancer Treat Rep 1983; 67: 223.
37. Casewel M, Phillips I. Food as a source of Klebsiella species for colonisation of intensive care patients J Clin Pathol 1978; 31: 845.
38. Aisner J, Schimpff S, Bennett J i sur. Aspergillus infection in cancer patients. Association with fireproofing materials in new hospitals JAMA 1976; 235: 411.
39. Nausell WM, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1983; 304: 448.
40. King K. Prophylactic non-absorbant antibiotics in leukemic patients. J Hyg (Camb) 1980; 85: 141-51.
41. Stoning RA, McElwain TJ, Jamenon B i sur. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukemia. Lancet 1977; 2: 837-40.
42. van der Waaij D, Berghuis de Vries J, Lekkerkerrk-van der Wees J i sur. Colonisation resistence of the digestive tract in conventional and antibiotic treated mice. J Hyg (Camb) 1971; 69: 405.
43. Gualtieri RJ, Donowitz GR, Kaiser DL i sur. Double-blind randomised study of prophylactic trimethoprim/sulfamethoxasole in granulocytopenic patients with hematologic malignances. Am J Med 1983; 74: 934-40.
44. Henry SA, Armstrong D, Kempin S i sur. Oral trimethoprim-sulfametoxasole in attempt to prevent infection after induction chemotherapy for acute leukemia. Am J Med 1984; 77: 663-66.
45. Karp JE, Merz WG, Hendricksen C i sur. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-contolled trial. Ann Intern Med 1987; 106: 1-7.
46. Winston DJ, Ho WG, Karp JE i sur. Norfloxacin for prevention of bacterial infections in granulocytopenic patient. Am J Med 1988; 82: 40-6.
47. Hughes W, Kuhn S, Chaudhary S i sur. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. New Engl J Med 1977; 279: 1419-29.
48. Dick JD, Merz WG, Saral R. Incidence of polyene resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980; 18: 158-63.
49. Meis J, Verweij P. Current management of fungal infections. Drugs 2001; 61 (suppl. 1): 13-25
50. Ezdinli EZ, O Sullivan DD, Wasser LP, Kim U, Stutzman L. Oral amphotericin B for candidiasis in patients with hematologic neoplasms: an autopsy study. JAMA 1979; 242: 258-260.
51. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10: 477-504.
52. Palmblad J, Lonnqvist B, Carlsson B i sur. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukemia in adults: more bacterias. J Intern Med 1992; 231: 363-70.
53. Goodman JL, Winston DJ, Greenfield RA i sur. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
54. Slavin MA, Osborne B, Adams R i sur. Efficacy and safety of fluconazole for fungal infections after marrow transplant. A prospective, randomised, double-blind study. J Infect Dis 1995; 171: 1545-52.
55. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-77.
56. Phaller MA, Lockhart SR, Pujol C i sur. Hospital specificity, region specificity, and fluconasole resistence of Candida albicans bloodstream isolates J Clin Microbiol 1998; 336: 1518-25.
57. van Burik JA, Bowden RA, McDonald G. Prophylactic fluconazole prevents candidal liver infection in marrow transplant patients(Abstract). Meeting of the American Gastroenterological Association and American Association for the Study of Liver Diseases, San Diego, May 18-23, 1996. Gastroenterology 1996; 110: A1350.
58. Van Wouth JW. Itraconazole in neutropenic patients. Chemoterapy1992; (supl. 1)38: 23-6.
59. Thunnissen PL, Sizoo W, Hendriks WD. Safety and efficancy of itraconazole in prevention of fungal infection in neutropenic patients. Netherland J Med 1991; 39(1-2): 84-91.
60. Huijgenns PC, Simoons-Smit AM, van Loenen AC i sur. Fluconasol versus itracionasole for the prevention of fungal infection in haemato-oncology. J Clin Pathol 1999; 52: 376-80.
61. Hughes WT, Armstrong D, Bodey GP, Feld R i sur. Guidelines for use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 61: 381-96.
62. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Inf Dis Clin North Am 1996; 10: 365-400.
63. Uzun A, Anaissie EJ. Antifungal prophylaxis in patiensts with hematological malignancies: a reappraisal. Blood 1995; 86: 2063-72.
64. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22(suppl 2): S133-S144.
65. Anaissie EJ, Darouiche RO, Abi-Said D i sur. Management of invasive candidal infections: results of prospective, rndomised, multicenter study of fluconazole versus amphotericin B and a review of the literature. Clin Infect Dis 1996; 23: 964-972.
66. Denning DW, Lee JY, Hostetler JS i sur. NIAID mycoses study group multicenter trial of oral itraconasole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
67. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993; 36: 421-4.
68. Boogaerts M, Garber G, Winston Di sur. Itraconazole compared with amphotericin B as empirical therapy for persistent fever of unknown origin in neutropenic patients. Bone Marow Transplant 1999; 23 Suppl. 1: S 111
69. Perfect J, Lutsar I, Gonzalez-Ruiz A. Voriconazole for treatment of resistant and rare fungal pathogenes. (abstract). 38th IDSA Meetings. New Orleans: 2000, 303.
70. Schlam H, Corey L, Brown J, Perfect. Voriconazole for salvage treatment of invasive aspergillosis (abstract). New Orleans: 38th IDSA Meetings, 2000, 304.
71. Graybill J. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Intern J Clin Practice 2001; 55: 633-638
72. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstruction in the management of refractory opportunistic fungal infection. Med Mycol 1998; 36(Suppl. 1): 12-25